Test Price
2,800 AED✅ Home Collection Available
PDGFB Gene Familial Meningioma Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
The PDGFB gene familial meningioma NGS test analyzes the entire coding region of the PDGFB gene for germline mutations linked to hereditary meningioma, enabling proactive surveillance and personalised risk management. This test is performed at DNA Labs UAE, a DHA-licensed facility (License 1143) with ISO 9001:2015 certification.
Test Overview & Methodology
This test employs Next-Generation Sequencing (NGS) to analyze the entire coding region of the PDGFB gene, detecting point mutations, small insertions/deletions, and copy-number variations with high sensitivity. The methodology includes targeted capture, high-depth sequencing on an Illumina platform, bioinformatics analysis with validation against reference genomes, and clinical interpretation by a board-certified geneticist.
| Feature | Our Test (PDGFB NGS) | Standard Single‑Gene Sanger Sequencing |
|---|---|---|
| Precision | > 99.9% sensitivity for point mutations, indels & copy-number variants | ~95% sensitivity; limited to point mutations |
| Methodology | Next‑Generation Sequencing (NGS) with bio‑informatic validation | Sanger sequencing, lower throughput |
| Turnaround Time | 3–4 Weeks (comprehensive report) | 4–6 Weeks |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) notes: “This NGS-based test identifies germline PDGFB mutations linked to hereditary meningioma, enabling early surveillance and family cascade testing. Results must be interpreted in the context of clinical history and genetic counseling. A positive result does not replace a physical exam or imaging; always consult your specialist before making medical decisions.”
Advisory: Medication & Result Interpretation
Important Advisory
Do not discontinue any prescribed medication or alter your treatment without consulting your physician. Genetic results are only one component of your health profile and must be interpreted alongside clinical findings.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals under 18 years without a legal guardian’s informed consent (in accordance with Federal Decree-Law No. 45 of 2021 and Federal Law No. 2 of 2019).
- Exclusion: Inability to provide adequate clinical history or genetic counselling records.
- ER Red Flags: Sudden severe headache, acute vision loss or double vision, new‑onset seizures, or focal neurological deficits – seek emergency care immediately. A genetic test appointment does not replace urgent evaluation.
Patient FAQ & Clinical Guidance
1. What is the PDGFB gene familial meningioma test?
This NGS-based test screens for mutations in the PDGFB gene linked to hereditary meningioma susceptibility, enabling early risk assessment. It targets the PDGFB (platelet-derived growth factor beta) gene, where germline alterations predispose individuals to multiple meningiomas. A positive finding guides screening protocols for at‑risk relatives.
2. How long does it take to receive results?
Results are typically available within 3 to 4 weeks from sample receipt, reflecting comprehensive sequencing and expert clinical interpretation. The 3–4 week period enables high‑depth NGS, bioinformatics analysis, and dual‑clinician sign‑off. Expedited options may be available upon request.
3. Is a blood sample required, and how is it collected?
Yes, we accept whole blood, extracted DNA, or a single drop of blood on an FTA card. Our DHA‑certified phlebotomists use cold‑chain transport for whole blood via VIP Mobile Phlebotomy (available daily 8 AM – 11 PM). Alternatively, a painless finger‑prick FTA card can be used for remote locations.
4. Who should consider this test?
Individuals with a personal or family history of meningioma, especially multiple or early‑onset cases, or those with known PDGFB-related syndromes. Genetic counseling is recommended before and after testing.
UAE Regulatory & Data Privacy Adherence
Compliance & Accreditation
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139)
- DHA Facility License Number: 1143 (Dubai Health Authority)
- Data Privacy: Strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Medical Liability: All clinical testing and patient consent procedures follow Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Minor Consent: Testing on individuals under 18 requires legal guardian consent per UAE PDPL and Federal Law No. 2 of 2019.
Clinical & Logistical Metadata
| Test Name | PDGFB Gene Familial Meningioma Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card blood spot |
| Methodology Used | Next‑Generation Sequencing (NGS) – targeted gene panel |
| ICD-10-CM Code | Z15.09 (Encounter for genetic susceptibility to other malignant neoplasm) |
| LOINC Code | 21636-6 (PDGFB gene mutation analysis) |
| DHA Facility License & Address | DHA License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians